Jpmorgan Chase & CO An2 Therapeutics, Inc. Transaction History
Jpmorgan Chase & CO
- $1.22 Trillion
- Q3 2024
A detailed history of Jpmorgan Chase & CO transactions in An2 Therapeutics, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 54 shares of ANTX stock, worth $90. This represents 0.0% of its overall portfolio holdings.
Number of Shares
54
Previous 1,020
94.71%
Holding current value
$90
Previous $2,000
100.0%
% of portfolio
0.0%
Previous 0.0%
Shares
6 transactions
Others Institutions Holding ANTX
# of Institutions
33Shares Held
13.5MCall Options Held
0Put Options Held
0-
Bml Capital Management, LLC Zionsville, IN5.75MShares$9.6 Million3.62% of portfolio
-
Ra Capital Management, L.P. Boston, MA2MShares$3.34 Million0.03% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA1.56MShares$2.6 Million0.22% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.04MShares$1.74 Million0.0% of portfolio
-
Acuitas Investments, LLC446KShares$744,4570.23% of portfolio
About AN2 Therapeutics, Inc.
- Ticker ANTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 19,402,700
- Market Cap $32.4M
- Description
- AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menl...